A Single Dose of Vero Cell-Derived Japanese Encephalitis (JE) Vaccine (Ixiaro) Effectively Boosts Immunity in Travelers Primed With Mouse Brain-Derived JE Vaccines
Open Access
- 13 June 2012
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (6), 825-834
- https://doi.org/10.1093/cid/cis542
Abstract
Background. A significant part of the world population lives in areas with endemic Japanese encephalitis (JE). For travelers from nonendemic countries, Vero cell–derived vaccine (JE-VC; Ixiaro) has replaced traditional mouse brain–derived vaccines (JE-MB) associated with safety concerns. The 2 vaccines are derived from different viral strains: JE-VC from the SA14-14-2 strain and JE-MB from the Nakayama strain. No data exist regarding whether JE-VC can be used to boost immunity after a primary series of JE-MB; therefore, a primary series of JE-VC has been recommended to all travelers regardless of previous vaccination history. Methods. One hundred twenty travelers were divided into 4 groups: Volunteers with no prior JE vaccination received primary immunization with (group 1) JE-MB or (group 2) JE-VC, and those primed with JE-MB received a single booster dose of (group 3) JE-MB or (group 4) JE-VC. Immune responses were tested before and 4–8 weeks after vaccination using plaque reduction neutralization test (PRNT) against both vaccine strains. Results. In vaccine-naive travelers, the vaccination response rate for test strains Nakayama and SA14-14-2 was 100% and 87% after primary vaccination with JE-MB and 87% and 94% after JE-VC, respectively. Antibody levels depended on the target virus, with higher titers against homologous than heterologous PRNT50 target strain (P < .001). In travelers primed with JE-MB, vaccination response rates were 91% and 91%, and 98% and 95% after a booster dose of JE-MB or JE-VC, respectively. Subgroup analysis revealed that a higher proportion of primed (98%/95%) than nonprimed (39%/42%) volunteers responded to a single dose of JE-VC (P < .001). Conclusions. A single dose of JE-VC effectively boosted immunity in JE-MB–primed travelers. Current recommendations should be reevaluated. Clinical Trials Registration. NCT01386827.Keywords
This publication has 37 references indexed in Scilit:
- Emergence of Genotype I of Japanese Encephalitis Virus as the Dominant Genotype in AsiaJournal of Virology, 2011
- Genotype V Japanese Encephalitis Virus Is EmergingPLoS Neglected Tropical Diseases, 2011
- Japanese encephalitis: update on vaccines and vaccine recommendationsCurrent Opinion in Infectious Diseases, 2010
- Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-upVaccine, 2010
- Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51Vaccine, 2010
- Japanese Encephalitis in Travelers from Non-Endemic Countries, 1973–2008The American Journal of Tropical Medicine and Hygiene, 2010
- Japanese Encephalitis in Travelers: Review of Cases and Seasonal RiskJournal of Travel Medicine, 2009
- Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51Vaccine, 2008
- Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines – Report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodiesBiologicals, 2008
- Protection against Japanese Encephalitis by Inactivated VaccinesThe New England Journal of Medicine, 1988